Tenderwize
Back to tender search

Non-exclusive discount agreement for Denosumab (Xgeva) products

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Jul 31, 2027 · 296 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

46 / 100

Complexity

58 / 100

Risk factors

The structured data shows a submission deadline of 2027-07-31, while the notice text states the first participation dea...

Participation documents must be downloaded from the DTVP project room after access approval, but the annexes themselves...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Jul 31, 2027

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements under §130a(8) SGB V for Denosumab/Xgeva products.
  • Products covered: Xgeva-branded products, biosimilars referencing the original Xgeva product, and corresponding import medicines.
Show full summary

Open-house notice for non-exclusive discount agreements under §130a(8) SGB V for Denosumab/Xgeva-related products (including biosimilars and corresponding imports). The procedure is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no exclusivity. Documents are available via DTVP, but the extracted procurement documents were not provided beyond the TED XML notice, so document-specific annexes were not analyzed.

Risks

The structured data shows a submission deadline of 2027-07-31, while the notice text states the first participation dea...

Participation documents must be downloaded from the DTVP project room after access approval, but the annexes themselves...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical company within the meaning of §4(18) AMG for the offered medicines.
  • The company must have its seat in Germany, another EU Member State, or another EEA Contracting State for the relevant medicines.

Eligibility

  • Submission of the completed declaration of no exclusion grounds is required.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive discount agreement for Denosumab (Xgeva) products

Supply lot for a non-exclusive discount agreement under §130a(8) SGB V covering medicinal products with the active substance Denosumab, limited to Xgeva-branded products, biosimilars referencing Xgeva, and corresponding import medicines. Open-house model; no exclusivity and no minimum purchase quantity guaranteed. Scope and lot information come from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Aug 2026 - May 2027

Category

Pharmaceutical products

Deadline

Deadline Jul 31, 2027

Procurement Details

Publication date
05 Jul 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
464454-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30